Distribution of CYP2C9∗3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin
- Author:
Yuanzhu WU
1
;
Jun LIU
1
;
Kui YANG
1
;
Jing PENG
1
;
Jiajie LUAN
1
;
Jun LIU
2
;
Kui YANG
2
;
Jing PENG
2
;
Jiajie LUAN
2
;
Jun WEI
3
;
Dafa ZHANG
3
;
Shuai SONG
4
;
Xiaolong YUAN
5
;
Zhongfang WANG
5
;
Nianbao ZHANG
6
;
Dan XIE
7
;
Peng JIANG
7
;
Jie FAN
8
Author Information
- Publication Type:Journal Article
- Keywords: 3; CYP2C9; gene polymorphism; individualized medication; VKORC1-1639G>A; warfarin
- From: Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(6):652-659
- CountryChina
- Language:Chinese
- Abstract: AIM: To study the distribution of CYP2C9∗3 and VKORC1-1639G>A gene polymorphism in Han population in Anhui province and their influence on the stable dose of warfarin. METHODS: The blood samples of 1 169 patients from 6 tertiary general hospitals in 5 areas of Anhui province from January 2020 to December 2021 were selected, the genotype of CYP2C9∗3 and VKORC1-1639G>A was detected by fluorescent staining in situ hybridization technique. RESULTS: The distribution of CYP2C9∗3 genotypes in 1 169 patients: the frequencies of AA, AC and CC genes were 90.16%, 9.24% and 0.60%, respectively; The distribution of VKORC1 genotype: the frequencies of AA, AG and GG genes were 84.26%, 14.71% and 1.03% respectively; There was no significant difference between the two genotypes in gender, age and regional distribution (P>0.05). The average daily warfarin dose of CYP2C9∗3 AA genotype in 755 patients with stable warfarin dose was (3.02±0.59) mg/d, which was significantly higher than patients with AC genotype and CC genotype; The average daily warfarin dose of patients with VKORC1-1639AA genotype was (2.72±0.40) mg/d, which was significantly lower than that of patients with AG genotype and GG genotype (P<0.05). And the difference was statistically significant (P<0.05); There are significant differences in gender, age and clinical diagnosis between patients with stable dose of warfarin and those without stable dose (P<0.05). CONCLUSION: CYP2C9 and VKORC1 genotypes are associated with the stable dose of warfarin. Clinical anticoagulation therapy guided by CYP2C9 and VKORC1 genotypes can provide guidance for individualized medication of warfarin.
